This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Romero, J. C. Articles by Rodicio, J. L. Search for Related Content PubMed PubMed Citation Articles by Romero, J. C. Articles by Rodicio, J. L.

Hypertension, Vol 10, 140-151, Copyright © 1987 by American Heart Association

ARTICLES

Multiple effects of calcium entry blockers on renal function in hypertension

JC Romero, L Raij, JP Granger, LM Ruilope and JL Rodicio

Characterization of the renal effects of calcium entry blockers has not been easy because the inhibition of Ca2+ cellular influx alters several regulatory functions. The ability of calcium blockers to dilate renal vasculature and to increase glomerular filtration rate is largely determined by the preexisting vascular tone. However, the increments in sodium excretion could occur without alterations in renal hemodynamics. Calcium blockers could increase sodium excretion by inducing a redistribution of renal blood flow toward juxtamedullary nephrons, by inhibiting tubuloglomerular feedback responses, or by a direct action on the tubular transport of sodium. These effects are poorly understood at present. In vitro studies show that the blockade of calcium entry enhances renin secretion and decreases prostaglandin synthesis. This dissociation has not been found during long-term administration, which has been proved to be effective for the treatment of essential hypertension with normal maintenance of renal function. In this respect, there are reports indicating that calcium blockers are particularly effective in a subgroup of patients with essential hypertension who exhibit subtle but detectable alterations in calcium metabolism. Further studies are needed to determine whether this significant response to calcium blockers is due to correction of an early defect of calcium cellular kinetics that initiated the increase in blood pressure.

This article has been cited by other articles:

				M. R. Weir, S. G. Chrysant, D. A. McCarron, M. Canossa-Terris, J. D. Cohen, P. A. Gunter, A. J. Lewin, R. F. Mennella, L. W. Kirkegaard, J. H. Hamilton, et al. Influence of Race and Dietary Salt on the Antihypertensive Efficacy of an Angiotensin-Converting Enzyme Inhibitor or a Calcium Channel Antagonist in Salt-Sensitive Hypertensives Hypertension, May 1, 1998; 31(5): 1088 - 1096. [Abstract] [Full Text] [PDF]

				M. T. Llinas, J. D. Gonzalez, F. Rodriguez, E. Nava, S. Taddei, and F. J. Salazar Renal Changes Induced by Nitric Oxide and Prostaglandin Synthesis Reduction : Effects of Trandolapril and Verapamil Hypertension, February 1, 1998; 31(2): 657 - 664. [Abstract] [Full Text] [PDF]

				K. Allikmets, T. Parik, R. Teesalu, and K. Allikmets Antihypertensive and Renal Effects of Isradipine in Essential Hypertension: Focus on Renin System Activity Angiology, November 1, 1997; 48(11): 977 - 983. [Abstract] [PDF]

				V. Gross, A. Lippoldt, W. Schneider, and F. C. Luft Effect of Captopril and Angiotensin II Receptor Blockade on Pressure Natriuresis in Transgenic TGR(mRen-2)27 Rats Hypertension, September 1, 1995; 26(3): 471 - 479. [Abstract] [Full Text]

				M. C. Houston, M. Weir, J. Gray, D. Ginsberg, C. Szeto, P. M. Kaihlenen, D. Sugimoto, M. Runde, and M. Lefkowitz The Effects of Nonsteroidal Anti-inflammatory Drugs on Blood Pressures of Patients With Hypertension Controlled by Verapamil Arch Intern Med, May 22, 1995; 155(10): 1049 - 1054. [Abstract] [PDF]

				P. M. ter Wee, A. G. De Micheli, and M. Epstein Effects of Calcium Antagonists on Renal Hemodynamics and Progression of Nondiabetic Chronic Renal Disease Arch Intern Med, June 13, 1994; 154(11): 1185 - 1202. [Abstract] [PDF]

				M.C. Houston, L. Olafsson, and M.C. Burger Effects of Nifedipine GITS and Atenolol Monotherapy on Serum Lipids, Blood Pressure, Heart Rate, and Weight in Mild to Moderate Hypertension Angiology, September 1, 1991; 42(9): 681 - 690. [Abstract] [PDF]

				E. Saunders, M. R. Weir, B. W. Kong, J. Hollifield, J. Gray, V. Vertes, J. R. Sowers, M. B. Zemel, C. Curry, J. Schoenberger, et al. A Comparison of the Efficacy and Safety of a {beta}-Blocker, a Calcium Channel Blocker, and a Converting Enzyme Inhibitor in Hypertensive Blacks Arch Intern Med, August 1, 1990; 150(8): 1707 - 1713. [Abstract] [PDF]

				N. M. Kaplan Calcium Entry Blockers in the Treatment of Hypertension: Current Status and Future Prospects JAMA, August 11, 1989; 262(6): 817 - 823. [Abstract] [PDF]